SB203580

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3-5 μM. SB203580 is a specific inhibitor of p38-MAPK pathway and is a new reversal agent of P-glycoprotein-mediated multidrug resistance. SB203580 suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model. SB203580 also inhibits protein kinase B (PKB, also known as Akt) and TLR signaling pathway.